New Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
/in Observational, Post-hoc/by MaxBone-Modifying Agents Linked to Improved Survival in Advanced Prostate Cancer
/in Observational, Retrospective studies/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/in Observational, Retrospective studies/by MaxThe Role of HSD3B1 in Prostate Cancer Progression and Treatment
/in Observational, Retrospective studies/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- A “Plug-and-Play” CAR-T That Could Be Updated as Cancer Changes September 23, 2026
- B7-H3 May Be Doing More Than Marking Prostate Cancer September 23, 2026
- New Phase 2 trial for JNJ-101556143 aka HLD-0915 in mCRPC / mAPMR Prostate Cancer September 22, 2026
- JUR-003 Enters Phase 1 Trial in Metastatic Prostate Cancer September 22, 2026